Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd (SHA:688336)
China · Delayed Price · Currency is CNY 60.42
+1.67 (2.84%)
At close: Feb 6, 2026
SHA:688336 Revenue
Sunshine Guojian Pharmaceutical (Shanghai) had revenue of 473.98M CNY in the quarter ending September 30, 2025, with 38.27% growth. This brings the company's revenue in the last twelve months to 1.37B, up 12.05% year-over-year. In the year 2024, Sunshine Guojian Pharmaceutical (Shanghai) had annual revenue of 1.19B with 17.70% growth.
Revenue (ttm)
1.37B
Revenue Growth
+12.05%
P/S Ratio
27.26
Revenue / Employee
1.38M
Employees
1,023
Market Cap
37.34B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1.19B | 179.53M | 17.70% |
| Dec 31, 2023 | 1.01B | 188.54M | 22.84% |
| Dec 31, 2022 | 825.49M | -103.32M | -11.12% |
| Dec 31, 2021 | 928.81M | 273.80M | 41.80% |
| Dec 31, 2020 | 655.01M | -522.39M | -44.37% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2014 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Pharmaron Beijing | 13.54B |
| Chongqing Zhifei Biological Products | 10.91B |
| Shanghai RAAS Blood Products | 7.95B |
| Beijing Tiantan Biological Products | 6.42B |
| Asymchem Laboratories (Tianjin) | 6.29B |
| Shanghai Allist Pharmaceuticals | 4.76B |
| Haisco Pharmaceutical Group | 4.27B |
| Hualan Biological Engineering | 4.27B |